{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:13:41Z","timestamp":1793196821182,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Fluoresc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Highly sensitive spectrofluorimetric methods were developed for the quantitative estimation of formoterol fumarate dihydrate (FFD) and fluticasone propionate (FP) in both authentic raw materials and marketed dosage forms using a micellar-enhanced spectrofluorimetric approach. The proposed methods are based on the determination of FP in the presence of FFD using the first derivative emission spectrofluorimetry. The peak amplitude of the emission spectra of the formed micellar fluorescence was measured at 465\u00a0nm after excitation at 236\u00a0nm (\u03bb max of FP).The second method quantifies FFD in the presence of FP using second derivative emission spectrofluorimetry. This method measures the peak amplitude of the emission spectra of the formed micelle at 283\u00a0nm, where there is no interference from FP, following excitation at 214\u00a0nm. In these methods, the emission spectra of the target drugs are measured after micellar formation, with excitation wavelengths at 214\u00a0nm for FFD and 236\u00a0nm for FP. The fluorescence intensity was enhanced using \u03b2-cyclodextrin as a micellar system after optimizing parameters affecting native fluorescence, such as diluting solvents, surfactants, and varying concentrations of \u03b2-cyclodextrin. A linear relationship was observed between the fluorescence intensity and concentration for FP over the range of 50\u2013100\u00a0ng\/mL and for FFD over the range of 30\u2013700\u00a0ng\/mL. The developed methods are simple, sensitive, non-extractive, economical, and suitable for routine analysis of FFD and FP in their raw materials and combined marketed dosage forms. The proposed techniques were carefully validated for linearity, accuracy, precision, and specificity according to the International Council for Harmonization (ICH) guidelines, demonstrating high sensitivity with lower limits of detection and quantitation. Additionally, the analytical greenness of the suggested procedures was assessed using the Analytical Greenness Metric Approach (AGREE), the Red\u2013Green\u2013Blue model, and the Green Procedure Analytical Index (GAPI).<\/jats:p>","DOI":"10.1007\/s10895-024-04100-1","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T16:52:28Z","timestamp":1737046348000},"page":"7945-7958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Green Assessment of Sensitive Spectrofluorimetric Methods for Simultaneous Estimation of Formoterol Fumarate and Fluticasone Propionate Using a Micelle-Mediated Approach"],"prefix":"10.1007","volume":"35","author":[{"given":"Hamees A.","family":"Adawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha A.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah S.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen\u00a0A.","family":"Boltia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"4100_CR1","unstructured":"United States Pharmacopoeia 30 (2020) National formulary 25. Rockville, USA, United States Pharmacopoeia Convention, Vol-II, pp 3653\u20133657, 3669\u20133670"},{"key":"4100_CR2","unstructured":"European pharmacopoeia (2019) EDQM publication, France, (2):2067\u201369"},{"key":"4100_CR3","first-page":"1824","volume-title":"Ministry of Health and Family Welfare, Indian Pharmacopoeia","author":"Government of India","year":"2019","unstructured":"Government of India (2019) Ministry of Health and Family Welfare, Indian Pharmacopoeia, vol II. Published by Indian Pharmacopoeia Commission, New Delhi, pp 1824\u20131825"},{"key":"4100_CR4","unstructured":"British pharmacopoeia\u00a0Commission. British Pharmacopoeia\u00a0(2019) Medicines and healthcare products regulatory agency (MHRA). London, TSO, Vol-III, pp 1087\u20131111"},{"key":"4100_CR5","first-page":"160","volume":"2","author":"KAM Attia","year":"2018","unstructured":"Attia KAM, Nasser MWI, El-Olemy A et al (2018) Different spectrophotometric methods applied for simultaneous analysis of binary mixture of formoterol and fluticasone: a comparative study. J Anal Pharm Res 2:160\u2013165","journal-title":"J Anal Pharm Res"},{"key":"4100_CR6","first-page":"323","volume":"79","author":"SA Boltia","year":"2024","unstructured":"Boltia SA, Hegazy MA, Adawy HA, Saad SS (2024) Spectrophotometric Approaches for Concurrent Estimation of Formoterol Fumarate Dihydrate and Fluticasone Propionate in their Binary Inhaler Combination. J Anal Chem 79:323\u2013334","journal-title":"J Anal Chem"},{"key":"4100_CR7","first-page":"5928","volume":"12","author":"AS Zanwar","year":"2014","unstructured":"Zanwar AS, Sen DB, Rucker DB, Seth AK (2014) Spectroscopic methods for the simultaneous estimation of mometasone furoate and Formoterol fumarate in rota caps. Indo Am J Pharm Res 12:5928\u20135933","journal-title":"Indo Am J Pharm Res"},{"key":"4100_CR8","first-page":"82","volume":"3","author":"NM Gurjar","year":"2012","unstructured":"Gurjar NM, Seth AK, Zanwar A, Patel J, Deshmukh G (2012) Development of first derivative spectroscopy method for estimation of budesonide and Formoterol in combine dosage form. Pharma Sci Men 3:82\u201392","journal-title":"Pharma Sci Men"},{"key":"4100_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.12991\/mpj.20162030844","volume":"20","author":"T Duygu","year":"2016","unstructured":"Duygu T, Gizem E, S\u0131d\u0131ka S (2016) A validated spectrophotometric method for determination of Formoterol fumarate dihydrate in bulk and dosage form using methyl orange as ion pair reagent. Marm Pharm J 20:275\u2013279","journal-title":"Marm Pharm J"},{"key":"4100_CR10","first-page":"611","volume":"5","author":"PD Shah","year":"2014","unstructured":"Shah PD, Koradia S (2014) Simultaneous determination of beclomethasone dipropionate and Formoterol fumarate in rota cap dosage form using two different spectrophotometric methods. World J Pharm Pharma Sci 5:611\u2013623","journal-title":"World J Pharm Pharma Sci"},{"key":"4100_CR11","first-page":"2230","volume":"6","author":"C Prasanthi","year":"2018","unstructured":"Prasanthi C, Madhavi K (2018) Development and Validation of Ultra Performance Liquid Chromatographic Method for the analysis of pulmonary. drug product containing formoterol fumarate dihydrate and fluticasone propionate. Int Res J Pharm 6:2230\u20138407","journal-title":"Int Res J Pharm"},{"key":"4100_CR12","doi-asserted-by":"publisher","unstructured":"Godge RK, Satpute SS, Sagar M, Patel AA et al\u00a0(2019) Development and validation of analytical method for simultaneous estimation of formoterol fumarate dihydrate and fluticasone propionate from bulk and dry powder inhaler formulation. J Drug Deliv Ther (3-s):212\u2013222.\u00a0https:\/\/doi.org\/10.22270\/jddt.v9i3-s.2827","DOI":"10.22270\/jddt.v9i3-s.2827"},{"key":"4100_CR13","first-page":"1148","volume":"3","author":"PP Raval","year":"2014","unstructured":"Raval PP, Dave JB, Joshi MP, Bhargav BK (2014) Estimation of Fluticasone propionate in nasal preparation and combination with Formoterol fumarate in inhalation preparation. World J Pharm Sci 3:1148\u20131160","journal-title":"World J Pharm Sci"},{"key":"4100_CR14","first-page":"77","volume":"6","author":"M Kusum","year":"2011","unstructured":"Kusum M, Davinder K, Vivek T, Satish K (2011) Simultaneous Quantitative Determination of Formoterol Fumarate and Fluticasone Propionate by Validated Reversed-Phase HPLC Method in Metered dose inhaler. Der Pharmacia Sinica 6:77\u201384","journal-title":"Der Pharmacia Sinica"},{"key":"4100_CR15","first-page":"27","volume":"5","author":"M Narendra","year":"2016","unstructured":"Narendra M, Gowekar R, Shailesh J (2016) Simultaneous Estimation of Formoterol Fumarate Dihydrate and Fluticasone Propionate in Dry Powder Inhalation Formulation by HPTLC. Der Pharma Chemica 5:27\u201332","journal-title":"Der Pharma Chemica"},{"key":"4100_CR16","first-page":"75","volume":"4","author":"BP Rajashi","year":"2019","unstructured":"Rajashi BP (2019) Suneela S D (Stability-Indicating High-Performance Thin-Layer Chromatography Method for Simultaneous Estimation of Formoterol Fumarate Dihydrate and Fluticasone Propionate in Bulk Drug and Pharmaceutical Dosage Form). Asian J Pharm & Clinic Res 4:75\u201392","journal-title":"Asian J Pharm & Clinic Res"},{"key":"4100_CR17","first-page":"113","volume":"75","author":"AS Yomna","year":"2019","unstructured":"Yomna AS, Hammouda EA, Mohamed A, Elashry M (2019) Multiple analytical methods for determination of formoterol and glycopyrronium simultaneously in their novel combined metered dose inhaler. BMC chemist 75:113\u2013130","journal-title":"BMC chemist"},{"key":"4100_CR18","first-page":"55","volume":"13","author":"S Aarti","year":"2021","unstructured":"Aarti S, Dhanya B, Charu P, Avinash K, Rajesh M, Ashim K (2021) Synchronized Quantitative Assessment of Corticosteroid and Bronchodilator in Rota caps by HPTLC using Fractional Factorial Design. Int J Pharm & Res 13:55\u201368","journal-title":"Int J Pharm & Res"},{"key":"4100_CR19","first-page":"1","volume":"60","author":"H Merey","year":"2016","unstructured":"Merey H, El-Mosallamy S, Hassan N, El-Zeany B (2016) Validated chromatographic methods for the simultaneous determination of Mometasone furoate and Formoterol fumarate dihydrate in a combined dosage form. Bull Pharm Cairo Univ 60:1\u201316","journal-title":"Bull Pharm Cairo Univ"},{"key":"4100_CR20","first-page":"80","volume":"5","author":"AS Patil","year":"2015","unstructured":"Patil AS (2015) Stability\u2013indicating High Performance Thin Layer Chromatography\/ densitometry estimation of Formoterol fumarate dihydrate in bulk and capsules. Int J Adv in Pharma 5:80\u201394","journal-title":"Int J Adv in Pharma"},{"key":"4100_CR21","first-page":"31","volume":"850","author":"DK Nadarassan","year":"2017","unstructured":"Nadarassan DK, Chrystyn H, Clark DJ, Assi KH (2017) (Validation of high-performance liquid chromatography assay for quantification of Formoterol in urine samples after inhalation using UV detection technique. J of Chroma Biomed Sci Appl 850:31\u201347","journal-title":"J of Chroma Biomed Sci Appl"},{"key":"4100_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.arabjc.2015.05.005","volume":"9","author":"RI El-Bagary","year":"2015","unstructured":"El-Bagary RI, Fouad MA, El-Shal MA, Tolba EH (2015) Forced degradation of mometasone furoate and development of two RP-HPLC methods for its determination with Formoterol fumarate or salicylic acid. Arab J Chem 9:493\u2013505","journal-title":"Arab J Chem"},{"key":"4100_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.saa.2015.05.026","volume":"149","author":"A Mohamed","year":"2015","unstructured":"Mohamed A, Omar MA, Hammad MA, Mohamed AA (2015) Spectrofluorimetric and micelle-enhanced spectrofluorimetric methods for determination of Felodipine and Nimodipine in pharmaceutical preparations and human plasma. Spectrochim Acta A Mol Biomol Spectrosc 149:934\u2013940. https:\/\/doi.org\/10.1016\/j.saa.2015.05.026","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"4100_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.molliq.2018.01.005","volume":"252","author":"F Ibrahim","year":"2018","unstructured":"Ibrahim F, El-Enany N, El-Shaheny R, Mikhail I (2018) Study of micelle and metal complexation-mediated fluorescence enhancements of raloxifene hydrochloride. Application to pharmaceutical analysis. J Mol Liq 252:408\u2013415. https:\/\/doi.org\/10.1016\/j.molliq.2018.01.005","journal-title":"J Mol Liq"},{"key":"4100_CR25","doi-asserted-by":"publisher","first-page":"54471","DOI":"10.1039\/c5ra06795b","volume":"5","author":"HW Darwish","year":"2015","unstructured":"Darwish HW, Bakheit AH (2015) Micellar enhanced synchronous spectrofluorimetric method for determination of dasatinib in tablets, human plasma and urine: application to in vitro drug release and content uniformity test. RSC Adv 5:54471\u201354480. https:\/\/doi.org\/10.1039\/c5ra06795b","journal-title":"RSC Adv"},{"key":"4100_CR26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.saa.2012.07.083","volume":"96","author":"K Kaur","year":"2012","unstructured":"Kaur K, Shivender SS, Ashok KM, Baldev S (2012) Micelle enhanced and terbium sensitized spectrofluorimetric determination of danofloxacin in milk using molecularly imprinted solid phase extraction. Spectrochim Acta A Mol Biomol Spectrosc 96:790\u2013795. https:\/\/doi.org\/10.1016\/j.saa.2012.07.083","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"4100_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.saa.2018.09.030","volume":"207","author":"M Aya","year":"2019","unstructured":"Aya M, Mustafa M, Azza H, Marwa FB, Fardous AM (2019) Micelle and inclusion complex enhanced spectrofluorimetric methods for determination of retigabine: Application in pharmaceutical and biological analysis. Spectrochim Acta A Mol Biomol Spectrosc. 207:251\u2013261. https:\/\/doi.org\/10.1016\/j.saa.2018.09.030","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc."},{"key":"4100_CR28","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.4314\/tjpr.v15i10.20","volume":"10","author":"D Hany","year":"2016","unstructured":"Hany D, Ahmed B, Ibrahim D (2016) Enhanced spectrofluorometric determination of the multitargeted tyrosine kinase inhibitor, crizotinib, in human plasma via micelle-mediated approach. Tropical J Pharm Res 10:2209\u20132217. https:\/\/doi.org\/10.4314\/tjpr.v15i10.20","journal-title":"Tropical J Pharm Res"},{"key":"4100_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.saa.2018.11.023","volume":"211","author":"AS Maha","year":"2019","unstructured":"Maha AS, Maha MA, Alastair WW, Marwa MA (2019) Stability indicating micellar enhanced spectrofluorimetric determination of daclatasvir in its tablet and spiked human plasma. Spectrochem Acta A Mol Biomol Spectrosc 211:52\u201358. https:\/\/doi.org\/10.1016\/j.saa.2018.11.023","journal-title":"Spectrochem Acta A Mol Biomol Spectrosc"},{"key":"4100_CR30","doi-asserted-by":"publisher","first-page":"12059","DOI":"10.1016\/j.saa.2021.120591","volume":"267","author":"MZ Abdullah","year":"2022","unstructured":"Abdullah MZ, Rasha AB, Fawzia AI (2022) First-order derivative synchronous spectrofluorimetric determination of two antihypertensive drugs, metolazone and valsartan, in pharmaceutical and biological matrices. Spectrochem Acta A Mol Biomol Spectrosc 267:12059\u201312071. https:\/\/doi.org\/10.1016\/j.saa.2021.120591","journal-title":"Spectrochem Acta A Mol Biomol Spectrosc"},{"key":"4100_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsps.2009.12.006","volume":"18","author":"M Rasha","year":"2010","unstructured":"Rasha M, Youssef A (2010) Determination of mirtazapine in spiked human plasma and tablets by first derivative spectrofluorimetric method. Saudi Pharm J 18:45\u201349","journal-title":"Saudi Pharm J"},{"key":"4100_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"WJ Poltka","year":"2018","unstructured":"Poltka WJ (2018) Anew tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. J Talanta 181:204\u2013209","journal-title":"J Talanta"},{"key":"4100_CR33","doi-asserted-by":"publisher","unstructured":"Aya A, Alaa EM, Yasser E, Aziza E\u00a0(2024) An ecofriendly first and second synchronous spectrofluorimetry for quantification of Florfenicol in presence of its different degradation products. Application to kinetic stability study. R Soc Open Sci 11:231642.\u00a0https:\/\/doi.org\/10.1098\/rsos.231642","DOI":"10.1098\/rsos.231642"},{"key":"4100_CR34","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.1021\/acs.analchem.9b01872","volume":"91","author":"MN Pawel","year":"2019","unstructured":"Pawel MN, Pawel K (2019) What Color Is Your Method? Adaptation of the RGB Additive Color Model to Analytical Method Evaluation. J Anal Chem 91:10343\u201310352","journal-title":"J Anal Chem"},{"key":"4100_CR35","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"P Francisco","year":"2020","unstructured":"Francisco P, Wojciech W, Marek T (2020) AGREE Analytical Greenness Metric Approach and Software. Anal Chem 92:10076\u201310082","journal-title":"Anal Chem"},{"key":"4100_CR36","unstructured":"ICH (2005) Harmonized tripartite guideline. Validation of analytical procedures: text and methodology. Q2(R1). Geneva, Current step 4 version"}],"container-title":["Journal of Fluorescence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10895-024-04100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10895-024-04100-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10895-024-04100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:12:55Z","timestamp":1762171975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10895-024-04100-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1007\/s10895-024-04100-1","relation":{},"ISSN":["1573-4994"],"issn-type":[{"value":"1573-4994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}